Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,332 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Regeneron Pharmaceuticals were worth $8,072,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Atomi Financial Group Inc. increased its position in Regeneron Pharmaceuticals by 4.9% in the 3rd quarter. Atomi Financial Group Inc. now owns 575 shares of the biopharmaceutical company’s stock valued at $605,000 after acquiring an additional 27 shares during the period. Daymark Wealth Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 20.3% during the third quarter. Daymark Wealth Partners LLC now owns 355 shares of the biopharmaceutical company’s stock valued at $373,000 after purchasing an additional 60 shares during the period. CWM LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock valued at $2,389,000 after purchasing an additional 25 shares in the last quarter. Wedmont Private Capital lifted its holdings in Regeneron Pharmaceuticals by 4.5% in the third quarter. Wedmont Private Capital now owns 1,496 shares of the biopharmaceutical company’s stock worth $1,490,000 after purchasing an additional 65 shares during the period. Finally, Adirondack Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 10 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN opened at $722.07 on Friday. The stock has a fifty day moving average price of $717.27 and a 200 day moving average price of $914.93. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The stock has a market cap of $79.35 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business earned $11.86 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.49%.

Analyst Ratings Changes

A number of analysts have recently weighed in on REGN shares. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $762.00 to $834.00 in a report on Wednesday. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.